In this episode, Dave talks with Dennis Walker about the Oakland PD raid on his church and them taking away $200,000 worth of sacraments. They also discuss the legal battle that is still ongoing as well as Dave's strategy to doing high dose trips utilizing more than 15 grams of dried psilocybin mushrooms.
A Canadian study found significant reductions in substance use after taking psychedelics, including alcohol and cocaine.
Jenalle talks with Spotlight about the cultivation of her journal company, Wakeful Travel, and her story of pivoting from a travel-focus to the integration space.
Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd:
www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20
Join our Newsletter (scroll to the bottom of the page and sign up):
https://psychedelicspotlight.com/
Follow us on Twitter:
James: @Psy_Invest
Maria: @psy_holy
The Psychedelic Investor: @PsycInvestor
Psychedelic Spotlight: @PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
Back to the potential MindMed, Compass Pathways & atai merger that Kevin O
Leary speculates on…
Kevin O’Leary Predicts These 3 Psychedelic Companies Will Merge, But Should They?
The “Shark Tank” star predicts three of the biggest psychedelic companies will merge into a mega-corporation, but our resident Psychedelic Investor wonders: Should they?
Famed investor Kevin O’Leary made a bold prediction last Tuesday, saying that psychedelic companies MindMed, atai Life Sciences and Compass Pathways will merge. For psychedelic stock investors, this would be a tsunami-sized event that would have ripple effects throughout the industry.
The Shark Tank star made the comments at the inaugural Benzinga Psychedelics Capital Conference in Miami, arguing that the companies “each need another $200 million by the time they get this to medicine.” In other words, as I have written before, the psychedelic medicines industry is heavily capital intensive, and getting multiple drugs from pre-clinical trials through Phase 3 trials and approved by the FDA can cost hundreds of millions of dollars.
Even though these companies are three of the best-financed in the industry — atai (Nasdaq: atai) has $362 million, Compass (Nasdaq: CMPS) has $273 million and MindMed (Nasdaq: MNMD, NEO: MMED) has $133 million — the celebrity investor believes that in order to succeed the companies may have to become one.
Read the entire article here: https://psychedelicspotlight.com/kevin-oleary-predicts-3-biggest-psychedelic-companies-will-merge-atai-mindmed-compass-pathways/
One man claims magic mushrooms healed his lost sense of smell. Read the full story here.
https://whyy.org/segments/could-magic-mushrooms-cure-covid-related-smell-loss/
A new anti-depressant study is out. Read the full study here: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0265928#sec011
#Mindmed #kevinoleary #psychedelicstocks
With no strong resistance manifesting to oppose the psychedelic renaissance, it appears these drugs have re-emerged from underground for a permanent place in our culture.
Dr. Matthew Johnson, one of the most published psychedelics researchers in the world, shares two decades worth of wisdom.
Understanding and learning Magic Mushrooms: Transformative and Healing Experiences
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.
